FindTrial
Sign In

Evaluation of Chemoresistance, Quality of Life and Economic Burden among Head and Neck Cancer Patients

Molecular Characterization of Chemoresistance in Cisplatin-treated Head and Neck Cancer Patients and its Impact on Quality of Life and Economic Burden - MCQE-HNC

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2022/10/046142
Enrollment
72
Registered
2022-10-04
Start date
Unknown
Completion date
Unknown
Last updated
2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C00-C14- Malignant neoplasms of lip, oral cavity and pharynx

Interventions

None listed

Sponsors

NGSM Institute of Pharmaceutical Sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: HNC Patients above 18 years of age. HNC patients who will undergo cisplatin therapy at least up 3rd cycle. HNC Patients willing to participate in the study.

Exclusion criteria

Exclusion criteria: HNC patients who will not receive cisplatin therapy HNC patients unwilling to participate in the study Pregnant HNC patients Critically ill Patients

Design outcomes

Primary

MeasureTime frame
Gene Expression for Cisplatin Resistance in Head and Neck CancerTimepoint: The gene expression will be evaluated at before cisplatin therapy, after the 3rd cycle of cisplatin therapy and after 3 months of cisplatin therapy—

Secondary

MeasureTime frame
Adverse effects of Therapy, economic burden, Quality of life, and Distress among Head and Neck Cancer patientsTimepoint: adverse effect will be evaluated at each cycle of cisplatin therapy, economic burden will be evaluated till the completion of chemotherapy cycle. however, quality of life and distress will be evaluated at before cisplatin therapy, after 3rd cycle, after 3 months and 6 months of cisplatin therapy.—

Countries

India

Contacts

Public ContactDr Uday Venkat Mateti

NGSM Institute of Pharmaceutical Sciences

udayvenkatmateti@gmail.com8152977460

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026